NEW YORK (GenomeWeb) – Certain Agilent Technologies mass spectrometers and liquid chromatography instruments now support Premier Biosoft's SimGlycan glycomics software as part of a deal announced today.

"Agilent and Premier Biosoft are focused on solving the glycan and glycopeptides identification problem in biopharmaceutical analyses," Premier Biosoft CEO Arun Apte said in a statement. "Combining our powerful instruments and software will enable researchers to generate, process, and analyze highly complex data so they can put it to use in drug development."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.